A detailed history of Pitcairn CO transactions in Genmab A/S stock. As of the latest transaction made, Pitcairn CO holds 10,901 shares of GMAB stock, worth $218,347. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,901
Previous 12,069 9.68%
Holding current value
$218,347
Previous $303,000 12.54%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$23.84 - $28.48 $27,845 - $33,264
-1,168 Reduced 9.68%
10,901 $265,000
Q2 2024

Aug 13, 2024

SELL
$25.13 - $30.27 $131,203 - $158,039
-5,221 Reduced 30.2%
12,069 $303,000
Q1 2024

May 13, 2024

BUY
$26.43 - $32.77 $51,802 - $64,229
1,960 Added 12.79%
17,290 $517,000
Q4 2023

Feb 14, 2024

BUY
$27.94 - $35.44 $89,184 - $113,124
3,192 Added 26.3%
15,330 $488,000
Q3 2023

Nov 13, 2023

BUY
$35.27 - $42.24 $428,107 - $512,709
12,138 New
12,138 $428,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Pitcairn CO Portfolio

Follow Pitcairn CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

News

Stay updated on Pitcairn CO with notifications on news.